This Week's CGT News: First Treg Therapy Approved - Takeaways - MDSpire
Advertisement
This Week's CGT News: First Treg Therapy Approved
First Treg-based cell therapy approved, FDA advanced therapy office faces fresh turnover, and preclinical CAR T studies target rare blood cancers and glioblastoma
The FDA has approved Tregzi, the first regulatory T cell-based immunotherapy for blood cancer patients undergoing stem cell transplantation.
2
Tregzi aims to improve chronic graft-versus-host disease-free survival in adults receiving allogeneic stem cell transplants.
3
The approval of Tregzi is supported by the PRECISION-T trial, which showed significant survival benefits compared to standard transplants.
4
Epicrispr's EPI-321 therapy may increase lean muscle volume in patients with facioscapulohumeral muscular dystrophy, according to early trial results.
5
New CAR T-cell therapies are being developed to target specific mutations in rare blood cancers and glioblastoma, showing promising preclinical results.
